Skip to main content

Advertisement

Table 3 Immunoreactivity of HNF-1B in PDAC and non-pancreatic carcinomas

From: Investigation of HNF-1B as a diagnostic biomarker for pancreatic ductal adenocarcinoma

Cancer type Total No. HNF-1B + Stain pattern Fisher’s exact p-value
Pancreatic primary 127 107 (84.3%) C, N, M ref
Cholangiocarcinoma 15 13 (86.7%) C, N, M .81
Ampullary 18 13 (72%) C, N, M .21
Gallbladder 14 13 (92.9%) C, N, M .69
Colorectal 39 0 <.001
Hepatocellular 20 0 <.001
Esophagus 11 3 (27.3%) C, N <.001
Stomach 14 9 (64.3%) C, N .13
Lung adenocarcinoma 24 6 (25%) C, N <.001
Lung Squamous cell 10 0 <.001
Breast 20 0 <.001
Bladder 18 7 (38.9%) C, N <.001
Prostate 15 4 (26.7%) C, N <.001
Kidney 21 16 (76.2%) N .35
Ovary 18 14 (77.8%) N, C .50
Uterus 21 10 (47.6%) N, C <.001
Metastatic PDAC 17 16 (94.1%) N, C  
Total No. 422    
  1. Abbreviations: PDAC, pancreatic ductal adenocarcinoma;
  2. SCC squamous cell carcinoma, C cytoplasmic, N nuclear, M membranous